U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C9H13NO2
Molecular Weight 167.205
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of 3-O-METHYLDOPAMINE

SMILES

COC1=C(O)C=CC(CCN)=C1

InChI

InChIKey=DIVQKHQLANKJQO-UHFFFAOYSA-N
InChI=1S/C9H13NO2/c1-12-9-6-7(4-5-10)2-3-8(9)11/h2-3,6,11H,4-5,10H2,1H3

HIDE SMILES / InChI

Molecular Formula C9H13NO2
Molecular Weight 167.205
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

3-Methoxytyramine (3-MT) is a human trace amine that occurs as a metabolite of the neurotransmitter dopamine. It has been shown to act as an agonist of human TAAR1, and an inhibitor of mitochondrial respiration. 3-MT has garnered research interest for its potential links and implications to Parkinson's disease and other Neurological disorders.

CNS Activity

Curator's Comment: CNS Active; but limited capacity to penetrate BBB.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Target ID: Q96RJ0
Gene ID: 134864.0
Gene Symbol: TAAR1
Target Organism: Homo sapiens (Human)
700.0 nM [EC50]
19.6 mM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Attenuation of circulatory shock and cerebral ischemia injury in heat stroke by combination treatment with dexamethasone and hydroxyethyl starch.
2010-10-11
Low penetrance of a SDHB mutation in a large Dutch paraganglioma family.
2010-06-11
Dysregulation of the norepinephrine transporter sustains cortical hypodopaminergia and schizophrenia-like behaviors in neuronal rictor null mice.
2010-06-08
In utero exposure to a low concentration of diesel exhaust affects spontaneous locomotor activity and monoaminergic system in male mice.
2010-03-23
Further evidence for aberrant prefrontal salience coding in schizophrenia.
2010
Human and mouse trace amine-associated receptor 1 have distinct pharmacology towards endogenous monoamines and imidazoline receptor ligands.
2009-10-23
Generation and characterization of conditional heparin-binding EGF-like growth factor knockout mice.
2009-10-14
Autologous bone marrow transplanation for extramedullary plasmacytoma presenting as adrenal incidentaloma.
2009-05-19
Isolation and identification of phase II enzyme-inducing agents from nonpolar extracts of green onion (Allium spp.).
2006-11-01
Enhanced dopamine uptake in the striatum following repeated restraint stress.
2005-09-01
Metabolism of homovanillamine to homovanillic acid in guinea pig liver slices.
2005
Assessment of O-methylated catecholamine levels in plasma and urine for diagnosis of autonomic disorders.
2004-11-30
The role of noradrenergic and dopaminergic hyperactivity in the development of spontaneous recurrence of methamphetamine psychosis and susceptibility to episode recurrence.
2004-10
Human brain dopamine metabolism in levodopa-induced dyskinesia and wearing-off.
2004-06
Inhibitory phenolic amides on lipopolysaccharide-induced nitric oxide production in RAW 264.7 cells from Beta vulgaris var. cicla seeds.
2003-09
Sources and significance of plasma levels of catechols and their metabolites in humans.
2003-06
Determination of catecholamines and metanephrines in urine by capillary electrophoresis-electrospray ionization-time-of-flight mass spectrometry.
2002-09-05
Factors for susceptibility to episode recurrence in spontaneous recurrence of methamphetamine psychosis.
2002-06
Analysis of S-nitroso-N-acetylpenicillamine effects on dopamine release in the striatum of freely moving rats: role of endogenous ascorbic acid and oxidative stress.
2001-02
Ketanserin reduces a particular monoamine pool in peripheral tissues.
1989-03
Increased monoamine metabolite concentrations and cholinesterase activities in cerebrospinal fluid of patients with acute stroke.
1987-12
Extractive acylation and mass spectrometric assay of 3-methoxytyramine, normetanephrine, and metanephrine in cerebrospinal fluid.
1985-09
Postmortem accumulation of 3-methoxytyramine in the brain.
1984-08-23
Determination of catecholamines by radioenzymatic assay using ion-pair liquid chromatography.
1981-04-10
Melanoma detection by enzyme-radioimmunoassay of L-dopa, dopamine, and 3-O-methyldopamine in urine.
1981-01
Determination of catecholamines and their 3-O-methylated metabolites in urine by mass fragmentography with use of deuterated internal standards.
1979-03
Determination of urinary normetanephrine, metanephrine, and 3-methoxytyramine by liquid chromatography, with amperometric detection.
1977-07
Postmortal accumulation of 3-methoxytyramine in brain.
1974
Patents

Sample Use Guides

Locomotor activity of DAT-KO and WT mice was measured in an Omnitech CCDigiscan. To assess effects of 3-MT in normal and TAAR1-KO mice, the animals were placed in the locomotor activity chamber and 30 min later various doses of 3-MT were administered i.c.v. over 4 minutes. After infusion, animals were put back into experimental chamber and behavior was monitored for 90 min after administration. 3-MT induced significant behavioral activation in DDD mice. Striatal tissue was collected from DDD mice treated with 36 µg of 3-MT 30 minutes after administration was analyzed for ERK activity. 3-MT caused a significant increase in the level of phosphorylated Erk2, thus indicating that certain receptor-mediated processes in striatal cells are affected by this treatment.
Route of Administration: Other
Mitochondria were isolated from whole brains of Sprague-Dawley rats. Mitochondria were suspended in 1 mL of incubation buffer containing 0.095MKCl, 0.075Mmannitol,0.025Msucrose, 0.005MKH2PO4, 0.020MTris-HCl, 0.001MEGTA, pH 7.4 (adjusted with KOH) at a final concentration of between 0.40 and 0.80 mg protein/mL. Malate and pyruvate were added to a final concentration of 10 mM. Oxygen consumption was carried out at 30°C in a closed chamber containing a Clark type oxygen electrode connected to a YSI model5300 oxygen monitor. Following a 10-minute incubation, resting conditions (no ADP) were monitored for 5 minutes, followed by the addition of ADP (0.25 mMfinal concentration) and measurement of active respiration. ADP depleted respiration was also monitored. Pre-incubation with the mitochondrial inhibitor 3-Methoxytyramine (3-MT) was carried out for15 min at 30°C prior to addition of ADP. Incubation with 3-MT was carried out in the dark for the first 10 minutes. IC50measurements represent the millimolar concentration of inhibitor required to inhibit 50% malate/pyruvate supported respiration compared with controls containing no inhibitor following a 15-min incubation at 30°C. 3-MT was found to inhibit brain mitochondrial respiration by MAO-dependent and -independent mechanisms. The IC50 of mitochondrial respiratory inhibition for 3-MT was determined to be 19.6 mM.
Substance Class Chemical
Created
by admin
on Wed Apr 02 12:45:03 GMT 2025
Edited
by admin
on Wed Apr 02 12:45:03 GMT 2025
Record UNII
JCH2767EDP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
3-METHOXY-P-TYRAMINE
Preferred Name English
3-O-METHYLDOPAMINE
Systematic Name English
4-(2-AMINOETHYL)-2-METHOXYPHENOL
Systematic Name English
4-HYDROXY-3-METHOXY-.BETA.-PHENETHYLAMINE
Systematic Name English
DOPAMINE HYDROCHLORIDE IMPURITY B [EP IMPURITY]
Common Name English
4-HYDROXY-3-METHOXYPHENYLETHYLAMINE
Systematic Name English
PHENOL, 4-(2-AMINOETHYL)-2-METHOXY-
Systematic Name English
HOMOVANILLINAMINE
Common Name English
HYDROXY-3-METHOXYPHENETHYLAMINE, 4-
Systematic Name English
2-METHOXY-4-(2-AMINOETHYL)PHENOL
Systematic Name English
4-HYDROXY-3-METHOXY-2-PHENETHYLAMINE
Systematic Name English
3-METHOXYTYRAMINE
Systematic Name English
GUAIACOL, 4-(2-AMINOETHYL)-
Systematic Name English
2-(4-HYDROXY-3-METHOXYPHENYL)ETHYLAMINE
Systematic Name English
4-HYDROXY-3-METHOXYPHENETHYLAMINE
Systematic Name English
HOMOVANILLYLAMINE
Systematic Name English
DOPAMINE IMPURITY B [EP IMPURITY]
Common Name English
Classification Tree Code System Code
LOINC 80156-3
Created by admin on Wed Apr 02 12:45:03 GMT 2025 , Edited by admin on Wed Apr 02 12:45:03 GMT 2025
LOINC 40409-5
Created by admin on Wed Apr 02 12:45:03 GMT 2025 , Edited by admin on Wed Apr 02 12:45:03 GMT 2025
LOINC 54343-9
Created by admin on Wed Apr 02 12:45:03 GMT 2025 , Edited by admin on Wed Apr 02 12:45:03 GMT 2025
LOINC 50140-3
Created by admin on Wed Apr 02 12:45:03 GMT 2025 , Edited by admin on Wed Apr 02 12:45:03 GMT 2025
LOINC 50139-5
Created by admin on Wed Apr 02 12:45:03 GMT 2025 , Edited by admin on Wed Apr 02 12:45:03 GMT 2025
LOINC 48381-8
Created by admin on Wed Apr 02 12:45:03 GMT 2025 , Edited by admin on Wed Apr 02 12:45:03 GMT 2025
LOINC 54344-7
Created by admin on Wed Apr 02 12:45:03 GMT 2025 , Edited by admin on Wed Apr 02 12:45:03 GMT 2025
LOINC 48380-0
Created by admin on Wed Apr 02 12:45:03 GMT 2025 , Edited by admin on Wed Apr 02 12:45:03 GMT 2025
LOINC 32618-1
Created by admin on Wed Apr 02 12:45:03 GMT 2025 , Edited by admin on Wed Apr 02 12:45:03 GMT 2025
Code System Code Type Description
MESH
C001746
Created by admin on Wed Apr 02 12:45:03 GMT 2025 , Edited by admin on Wed Apr 02 12:45:03 GMT 2025
PRIMARY
PUBCHEM
1669
Created by admin on Wed Apr 02 12:45:03 GMT 2025 , Edited by admin on Wed Apr 02 12:45:03 GMT 2025
PRIMARY
FDA UNII
JCH2767EDP
Created by admin on Wed Apr 02 12:45:03 GMT 2025 , Edited by admin on Wed Apr 02 12:45:03 GMT 2025
PRIMARY
WIKIPEDIA
3-Methoxytyramine
Created by admin on Wed Apr 02 12:45:03 GMT 2025 , Edited by admin on Wed Apr 02 12:45:03 GMT 2025
PRIMARY
CAS
554-52-9
Created by admin on Wed Apr 02 12:45:03 GMT 2025 , Edited by admin on Wed Apr 02 12:45:03 GMT 2025
PRIMARY
RXCUI
1742513
Created by admin on Wed Apr 02 12:45:03 GMT 2025 , Edited by admin on Wed Apr 02 12:45:03 GMT 2025
PRIMARY
EPA CompTox
DTXSID40862189
Created by admin on Wed Apr 02 12:45:03 GMT 2025 , Edited by admin on Wed Apr 02 12:45:03 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> METABOLITE INACTIVE